Induction of metabolic syndrome in GDF-15 knock-out mice revealed that IL-4, IL-13, or rosiglitazone-based treatments depend on the JAK/STAT6- or PPARγ-dependent upregulation of GDF-15 in macrophages. The gene discussed is GDF15; the disease is metabolic syndrome.